Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MedCaP: BM-MSC in Pediatric Cardiac Surgery
NCT04236479Phase 1Active, not recruiting
- Sponsor
- Catherine Bollard
- Start
- Jul 2020
- Primary completion
- Dec 2026
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic bone marrow-derived mesenchymal stromal cells in congenital heart disease (CHD), sponsored by Catherine Bollard. Primary endpoint: Number of subjects who experience serious adverse events, adverse events, and/or early treatment discontinuations at 45 days. Started Jul 2020; status: active, not recruiting.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
congenital heart disease (CHD)
Beyond the preview
Go deeper on NCT04236479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04236479.